Skip to main content
Equibles
BMY logo

BMY · Bristol Myers Squibb Co · Investor Relations

Track BMY — free

Use BMY with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BMY.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$63.43 +1.11 (+1.78%) At close · Nov 13 Play latest call Q3 2026 earnings call transcript
S&P 500 member Russell 1000 member Rebalance outlook locked
Market Cap
$129.66B
Shares
2.04B
Volume · Nov 13 9.27M Avg daily vol (3M) 10.87M

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-11-12 Bristol Myers Squibb Announces Evolution of Research & Development Organization
2026-11-06 Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) for Camzyos (mavacamten) at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions
2026-11-06 Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) for Camzyos (mavacamten) at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions
2026-10-29 Bristol Myers Squibb Reports Third Quarter Financial Results for 2026
2026-10-29 Bristol Myers Squibb Reports Third Quarter Financial Results for 2026
2026-10-26 Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study
2026-10-26 Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study
2026-10-25 BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy
2026-10-25 BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy
2026-10-23 Izalontamab Brengitecan (Iza-Bren) Reduced Risk of Disease Progression or Death by 59% versus Chemotherapy in Patients with Advanced HR+/HER2- Breast Cancer in Phase 3 PANKU-Breast01 Study
2026-10-23 Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients with Highly Active Relapsing and Progressive Forms of Multiple Sclerosis at MSToronto 2026
2026-10-19 Bristol Myers Squibb to Showcase Next-Generation Cancer Modalities and Leadership Across Solid Tumors at ESMO 2026
2026-10-12 Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint
2026-10-12 Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio’s Radiopharmaceutical Therapy, in Patients with GEP-NETs
2026-10-08 Bristol Myers Squibb Announces ZENBEXUS (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refractory Multiple Myeloma in Phase 3...
2026-10-01 Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement
2026-09-30 U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients*
2026-09-25 Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma
2026-09-18 Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026

Past events

Date Event Type
2026-10-29 Bristol Myers Squibb Q3 2026 Results Conference Call Earnings call
2026-07-30 Bristol Myers Squibb Q2 2026 Results Conference Call Earnings call
2026-06-09 Goldman Sachs 47th Annual Global Healthcare Conference Conference
2026-05-14 Bank of America Securities Health Care Conference Conference
2026-04-30 Bristol Myers Squibb Q1 2026 Results Conference Call Earnings call
2026-02-05 Earnings conference call (announced in 8-K) Earnings call

Source: https://www.bms.com/investors.html

Key facts CIK 14272 CUSIP 110122108 13F (30d) 2056 filings 1929 filers Visit website Investor relations